US Patent

US10959943 — Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa

Method of Use · Assigned to Sunovion Pharmaceuticals Inc · Expires 2036-04-19 · 10y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods and dosage forms for treating Parkinson's disease by administering apomorphine to the oral mucosa.

USPTO Abstract

Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2825 — apomorphine-hydrochloride
U-2825 — apomorphine-hydrochloride
U-2825 — apomorphine-hydrochloride
U-2825 — apomorphine-hydrochloride
U-2825 — apomorphine-hydrochloride

Patent Metadata

Patent number
US10959943
Jurisdiction
US
Classification
Method of Use
Expires
2036-04-19
Drug substance claim
No
Drug product claim
No
Assignee
Sunovion Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.